Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 4/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 5/20 | 0.34 |
| ▸ | FAP | Q12884 | 5/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31001801 | 0.81 | KDM4E (0.35) | HTR6NPC1RAB9AMAPTSMN1; SMN2 | |
| SCHEMBL18120359 | 0.80 | HTR6 (0.33) | HTR6PTGS2NPC1RAB9AMAPT | |
| SCHEMBL23047161 | 0.80 | PDE10A (0.44) | HTR6PTGS2NPC1RAB9AMAPT | |
| SCHEMBL21033308 | 0.76 | HTR6 (0.41) | HTR6PTGS2TYK2ALDH1A1HPGD | |
| SCHEMBL31001747 | 0.76 | TGFBR1 (0.31) | — | |
| SCHEMBL31001899 | 0.76 | KMT2A (0.33) | HTR6PTGS2SMN1; SMN2PDE10A | |
| SCHEMBL15306534 | 0.74 | HTR6 (0.38) | HTR6PTGS2NPC1RAB9AMAPT | |
| SCHEMBL21001663 | 0.73 | KDM4E (0.45) | HTR6PTGS2TYK2RAB9AMAPT | |
| SCHEMBL21033150 | 0.73 | HTR6 (0.39) | HTR6PTGS2DPP4FAPDPP8 | |
| SCHEMBL24066067 | 0.73 | HTR6 (0.36) | HTR6PTGS2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9790169-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-17 | — | — | US | disclosed |
| US-20170231999-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-17 | — | — | US | disclosed |
| US-20160289171-A1 | IDO INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170231999-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | HTR6 387/4885PTGS2 323/4885DPP4 315/4885 |
| US-20160289171-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | HTR6 387/4885PTGS2 323/4885DPP4 315/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.